Navigation Links
Molecular regulation of hypoxic-ischemic brain damage
Date:5/12/2014

Oligodendrocyte lineage gene 1 (Olig1) plays a key role in hypoxic-ischemic brain damage and myelin repair. miRNA-9 is involved in the occurrence of many related neurological disorders. Bioinformatics analysis demonstrated that miRNA-9 complementarily, but incompletely, bound oligodendrocyte lineage gene 1, but whether miRNA-9 regulates oligodendrocyte lineage gene 1 remains poorly understood. Dr. Lijun Yang and co-workers from Beijing Friendship Hospital, Capital Medical University in China prepared whole brain slices from a rat model of oxygen-glucose deprivation and explored dynamic expression pattern of Olig1 during hypoxic-ischemic brain damage and after miRNA-9 transfection. Results from their study showed that miRNA-9 possibly negatively regulated oligodendrocyte lineage gene 1 in brain tissues during hypoxic-ischemic brain damage. The relevant study has been reported in the Neural Regeneration Research (Vol. 9, No. 5, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Molecular switches age-related memory decline? Genetic variant protect against brain aging
2. Molecular tumor board helps in advanced cancer cases
3. Researchers find the accelerator for molecular machines
4. Scripps Florida scientists reveal molecular secrets behind resveratrols health benefits
5. MRI, on a molecular scale
6. Researchers develop novel molecular blood group typing technique
7. Self-assembled superlattices create molecular machines with hinges and gears
8. Mechanical forces driving breast cancer lead to key molecular discovery
9. Fighting antibiotic resistance with molecular drill bits
10. Exchange rate behaves like particles in a molecular fluid
11. MARC Travel Awards announced for Association of Biomolecular Resource Facilities Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecular regulation of hypoxic-ischemic brain damage
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... and GREENWICH, Conn. , Feb. ... firm focused on venture growth investments in biotechnology ... Josh Richardson , M.D. to Managing Director. ... biotechnology companies.  He is a board observer at ... in Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology: